Related references
Note: Only part of the references are listed.SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mfolfirinox versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.
Davendra Sohal et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.
Margaret A. Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial
Jin-Young Jang et al.
ANNALS OF SURGERY (2018)
Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
E. Versteijne et al.
BRITISH JOURNAL OF SURGERY (2018)
Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.
Geertjan Van Tienhoven et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis
Ali A. Mokdad et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma
B. Ielpo et al.
EJSO (2016)
APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
Margaret A. Tempero et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka et al.
LANCET (2016)
Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3
M. M. Vickers et al.
PANCREATOLOGY (2016)
Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head
Waseem Lutfi et al.
SURGERY (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial
Werner Scheithauer et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Pathological response to neoadjuvant gemcitabine plus nabpaclitaxel in pancreatic adenocarcinoma to improve survival
Rafael Alvarez-Gallego et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Meta-analysis of radical resection rates and margin assessment in pancreatic cancer
M. D. Chandrasegaram et al.
BRITISH JOURNAL OF SURGERY (2015)
Pathology reporting of pancreatic cancer following neoadjuvant therapy: Challenges and uncertainties
C. Verbeke et al.
CANCER TREATMENT REVIEWS (2015)
A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
Eileen M. O'Reilly et al.
ANNALS OF SURGERY (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma
Pablo E. Serrano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association
Mahmoud M. Al-Hawary et al.
RADIOLOGY (2014)
Final results for gemcitabine with nab-paclitaxel in neoadjuvant treatment of resectable pancreatic adenocarcinoma: GAIN-1 study
Sarunas Sliesoraitis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pancreatic Ductal Adenocarcinoma Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a True R0 Resection?
Ioannis T. Konstantinidis et al.
ANNALS OF SURGERY (2013)
Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer
Makoto Shinoto et al.
CANCER (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
Wei-Chih Liao et al.
LANCET ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial
Ralf-Dieter Hofheinz et al.
LANCET ONCOLOGY (2012)
Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer
Hidehiro Tajima et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2012)
Pancreatic Cancer Surgery in the New Millennium Better Prediction of Outcome
Werner Hartwig et al.
ANNALS OF SURGERY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response
O. Turrini et al.
EJSO (2010)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
Sonja Gillen et al.
PLOS MEDICINE (2010)
Margin Clearance and Outcome in Resected Pancreatic Cancer
David K. Chang et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
Gauri R. Varadhachary et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prospective phase II trial of Neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head
Stefan Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
Douglas B. Evans et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
Chandrajit P. Raut et al.
ANNALS OF SURGERY (2007)
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: Gemcitabine alone versus gemcitabine combined with cisplatin
Daniel H. Palmer et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial
Francoise Mornex et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer
R Ryan et al.
HISTOPATHOLOGY (2005)
Share Paper
